NCT03781479View on ClinicalTrials.gov

Controlled Trial to Evaluate Amifampridine Phosphate in Spinal Muscular Atrophy Type 3 Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

January 21, 2019

Primary Completion Date

July 23, 2020

Study Completion Date

July 23, 2020

Conditions
Muscular Atrophy, Spinal
Interventions
DRUG

Amifampridine Phosphate

Amifampridine phosphate tablets 10 mg will be provided in round, white-scored tablets, and containing amifampridine phosphate formulated to be the equivalent of 10 mg amifampridine base per tablet.

DRUG

Placebo Oral Tablet

Placebo Oral Tablet

Trial Locations (1)

20133

Neurological Institute Carlo Besta, Milan

Sponsors
All Listed Sponsors
lead

Catalyst Pharmaceuticals, Inc.

INDUSTRY

NCT03781479 - Controlled Trial to Evaluate Amifampridine Phosphate in Spinal Muscular Atrophy Type 3 Patients | Biotech Hunter | Biotech Hunter